Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
To accelerate the development of next-generation radioconjugates to treat cancer
Subscribe To Our Newsletter & Stay Updated